Business Context and Reporting Period
This Form 8-K Current Report was filed by Viking Therapeutics, Inc. on February 2, 2018. The filing discloses the entry into a material definitive agreement regarding an underwritten public offering of the Company's common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 11,000,000 shares of Common Stock.
- Public Offering Price: $5.00 per share.
- Underwriter Purchase Price: $4.65 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to an additional 1,650,000 shares within 30 days.
- Expected Gross Proceeds: Approximately $55.0 million (excluding over-allotment and before deducting underwriting discounts and expenses).
- Expected Closing Date: On or about February 6, 2018.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with William Blair & Company, L.L.C. as the representative. The agreement includes customary representations, warranties, indemnification provisions, and termination clauses. Additionally, the Company's directors and executive officers have entered into "lock-up" agreements prohibiting the sale or transfer of Company securities until May 3, 2018, without prior written consent.
Outlook, Risks, and Contingencies
The closing of the offering is subject to the satisfaction of customary closing conditions. The filing includes forward-looking statements regarding the anticipated closing and proceeds, which are subject to risks such as the Company's ability to satisfy closing conditions and general market conditions. The Company explicitly states it does not intend to revise or update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date and actual proceeds received after deducting underwriting discounts and offering expenses.
- Confirm whether the underwriters exercised the over-allotment option for the additional 1,650,000 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination rights.
- Monitor compliance with the lock-up agreement expiration on May 3, 2018.